Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon, Inc. director William H. Carson reported an open-market purchase of 8,000 shares of Common Stock at $5.67 per share. Following this transaction, he directly owns 62,405 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Annexon, Inc.’s chief medical officer, Jamie Dananberg, reported an open-market sale of 5,820 shares of common stock. The shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this tax-related sale, Dananberg still holds 123,582 Annexon common shares directly.
Annexon, Inc. executive Michael Overdorf, EVP & Chief Business Officer, reported an open-market sale of 4,339 shares of common stock at a weighted average price of $5.42 per share. The filing states the shares were sold to cover tax withholding obligations related to vesting restricted stock units. After this transaction, Overdorf beneficially owns 182,625 shares of Annexon common stock directly.
Annexon, Inc. executive vice president and chief innovation officer Ted Yednock reported an open-market sale of 5,566 shares of common stock at a weighted average price of $5.42 per share on March 2, 2026. The sale was made to cover tax withholding obligations from vesting RSUs, leaving him with 154,161 directly owned shares.
Annexon, Inc. executive vice president and chief scientific officer Dean Richard Artis sold 5,894 shares of common stock on March 2, 2026 in an open-market transaction to cover tax withholding obligations from vested restricted stock units. The weighted average sale price was $5.43 per share, and he held 180,093 shares afterward.
Annexon, Inc. Executive Vice President and Chief Financial Officer Jennifer Lew reported an open-market sale of 5,565 shares of common stock at a weighted average price of $5.42 per share. The shares were sold on March 2, 2026 to cover tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, she held 170,700 shares of Annexon common stock directly.
ANNX proposed sale of 5,566 common shares under a Form 144, tied to restricted stock vesting dated 02/27/2026.
The excerpt also shows a prior sale of 7,857 common shares on 02/18/2026 and a reported share count of 119,632,804 as of 03/02/2026.
ANNX reports a Rule 144 notice listing 5,894 common shares to be sold by the holder and 5,290 shares sold in the past three months. The filing names Fidelity Brokerage Services LLC as the broker/holder and shows the transaction type as Restricted Stock Vesting with the action labeled Compensation.
ANNX submitted a Rule 144 notice relating to proposed sales of its Common stock. The filing lists 4,339 Common shares tied to restricted stock vesting dated 02/27/2026 and discloses that Michael Overdorf sold 6,225 Common shares on 02/18/2026 with a reported amount of $31,764.30.
ANNX filed a Form 144 notice stating an intended sale of 5,820 common shares under Rule 144 on 02/27/2026 tied to restricted stock vesting. The filing also records a prior sale of 5,290 shares on 02/18/2026 by Jamie Dananberg.